Literature DB >> 2819042

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.

C M Lin1, H H Ho, G R Pettit, E Hamel.   

Abstract

Combretastatin A-4 (CS-A4), 3,4,5-trimethoxy-3'-hydroxy-4'-methoxy-(Z)-stilbene, and combretastatin A-2 (CS-A2), 3,4-(methylenedioxy)-5-methoxy-3'-hydroxy-4'-methoxy-(Z)-stilbene, are structurally simple natural products isolated from the South African tree Combretum caffrum. They inhibit mitosis and microtubule assembly and are competitive inhibitors of the binding of colchicine to tubulin [Lin et al. (1988) Mol. Pharmacol. 34, 200-208]. In contrast to colchicine, drug effects on tubulin were not enhanced by preincubating CS-A4 or CS-A2 with the protein. The mechanism of their binding to tubulin was examined indirectly by evaluating their effects on the binding of radiolabeled colchicine to the protein. These studies demonstrated rapid binding of both compounds to tubulin even at 0 degrees C (binding was complete at the earliest times examined), in contrast to the relatively slow and temperature-dependent binding of colchicine. Although the binding of the C. caffrum compounds to tubulin was quite tight, permitting ready isolation of near-stoichiometric amounts of drug-tubulin complex even in the absence of free drug, both CS-A4 and CS-A2 dissociated rapidly from tubulin in the presence of high concentrations of radiolabeled colchicine. Apparent rate constants for drug dissociation from tubulin at 37 degrees C were 3.2 x 10(-3) s-1 for CS-A4, 4.8 x 10(-3) s-1 for CS-A2, and 2.9 x 10(-5) s-1 for colchicine (half-lives of 3.6, 2.4, and 405 min, respectively). Thus, the effectiveness of the C. caffrum compounds as antimitotic agents appears to derive primarily from the rapidity of their binding to tubulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2819042     DOI: 10.1021/bi00443a031

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  91 in total

1.  Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Delia Preti; Mojgan Aghazadeh Tabrizi; Andrea Brancale; Xian-Hua Fu; Jun Li; Su-Zhan Zhang; Ernest Hamel; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2011-12-21       Impact factor: 7.446

2.  Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.

Authors:  Giuseppe La Regina; Ruoli Bai; Willeke Rensen; Antonio Coluccia; Francesco Piscitelli; Valerio Gatti; Alessio Bolognesi; Antonio Lavecchia; Ilaria Granata; Amalia Porta; Bruno Maresca; Alessandra Soriani; Maria Luisa Iannitto; Marisa Mariani; Angela Santoni; Andrea Brancale; Cristiano Ferlini; Giulio Dondio; Mario Varasi; Ciro Mercurio; Ernest Hamel; Patrizia Lavia; Ettore Novellino; Romano Silvestri
Journal:  J Med Chem       Date:  2011-11-21       Impact factor: 7.446

3.  Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Olga Cruz-Lopez; Carlota Lopez Cara; Maria Dora Carrion; Andrea Brancale; Ernest Hamel; Longchuan Chen; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

4.  Direct photoaffinity labeling of tubulin with colchicine.

Authors:  J Wolff; L Knipling; H J Cahnmann; G Palumbo
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action.

Authors:  Aldo Andreani; Massimiliano Granaiola; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Lucilla Varoli; Natalia Calonghi; Concettina Cappadone; Giovanna Farruggia; Claudio Stefanelli; Lanfranco Masotti; Tam L Nguyen; Ernest Hamel; Robert H Shoemaker
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

6.  Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype.

Authors:  Mikhail Krasavin; Andrey V Sosnov; Ruben Karapetian; Igor Konstantinov; Olga Soldatkina; Elena Godovykh; Fedor Zubkov; Ruoli Bai; Ernest Hamel; Andrei A Gakh
Journal:  Bioorg Med Chem Lett       Date:  2014-08-08       Impact factor: 2.823

Review 7.  A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Authors:  Dietmar W Siemann; David J Chaplin; Patricia A Walicke
Journal:  Expert Opin Investig Drugs       Date:  2009-02       Impact factor: 6.206

8.  Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.

Authors:  Wolfgang Dohle; Mathew P Leese; Fabrice L Jourdan; Christopher J Chapman; Ernest Hamel; Eric Ferrandis; Barry V L Potter
Journal:  ChemMedChem       Date:  2014-05-12       Impact factor: 3.466

9.  A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent.

Authors:  Yali Kong; Kan Wang; Michael C Edler; Ernest Hamel; Susan L Mooberry; Mikell A Paige; Milton L Brown
Journal:  Bioorg Med Chem       Date:  2009-11-10       Impact factor: 3.641

10.  New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies.

Authors:  Giuseppe La Regina; Taradas Sarkar; Ruoli Bai; Michael C Edler; Roberto Saletti; Antonio Coluccia; Francesco Piscitelli; Lara Minelli; Valerio Gatti; Carmela Mazzoccoli; Vanessa Palermo; Cristina Mazzoni; Claudio Falcone; Anna Ivana Scovassi; Vincenzo Giansanti; Pietro Campiglia; Amalia Porta; Bruno Maresca; Ernest Hamel; Andrea Brancale; Ettore Novellino; Romano Silvestri
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.